Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin as Adjunctive to Insulin in T1DM (EASE-3)
NCT02580591Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2015
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 24
01
Overview
A Phase 3 trial of empagliflozin in type 1 diabetes mellitus (T1D), sponsored by Boehringer Ingelheim. Started Dec 2015; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02580591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02580591.